Pharma BD Deal Intelligence

Gilead Sciences, Inc. / HOOKIPA Pharma Inc.

2025 · Asset Purchase · $10M · Complete

Gilead Sciences agreed to acquire HOOKIPA Pharma's assets for the HB-400 chronic hepatitis B program and certain assets of the HB-500 HIV program, both previously developed under the parties' 2022 amended and restated research collaboration and license agreement. Consideration is up to $10 million in cash, with $3 million payable at closing and up to $7 million in staged transfer-completion payments. The sale required HOOKIPA stockholder approval and closed on October 30, 2025.

Key facts

• Announced May 21, 2025
• Deal value $10M
• Deal type Asset Purchase
• Therapeutic area Infectious Disease

Related deals

• Gilead Sciences, Inc. / Calistoga Pharmaceuticals, Inc. (2011)
• Gilead Sciences, Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) (2016)
• Gilead Sciences, Inc. / Galapagos NV (2016)
• Gilead Sciences, Inc. / YM BioSciences Inc. (2012)
• Gilead Sciences, Inc. / Assembly Biosciences, Inc. (2025)
• Gilead Sciences, Inc. / Sprint Bioscience AB (2025)

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Gilead Sciences, Inc. deals  ·  Infectious Disease deals